Roivant director sells 20K shares at ~$40

A Roivant Sciences director exercised 20,000 options and sold 20,000 shares under a Rule 10b5-1 trading plan at about five times the exercise price.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported an option exercise and same-day sale of common shares. On September 8, 2026, she exercised options for 20,000 shares at $8.80 per share, then sold 20,000 common shares at a weighted average price between $39.90 and $40.00 per share under a Rule 10b5-1 trading plan. Following the exercise, she held 18,578 stock options that remain exercisable until April 19, 2033.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Fitzgerald Meghan

Role Director

Sold 20,000 shs ($798K)

Approx. gross sale proceeds $798K

Approx. exercise cost $176K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	20,000	$0.00	$0.00
Exercise	Common Shares	20,000	$8.80	$176K
Sale	Common Shares F1	20,000	$39.90	$798K

Holdings After Transaction: Stock Option (Right to Buy) — 18,578 contracts (Direct); Common Shares — 42,963 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
2. F2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options exercised: 20,000 options Exercise price: $8.80 per share Shares sold: 20,000 shares +5 more

8 metrics

Options exercised 20,000 options Stock options for common shares exercised on September 8, 2026

Exercise price $8.80 per share Price paid to exercise 20,000 stock options

Shares sold 20,000 shares Common shares sold on September 8, 2026

Weighted average sale price $39.90 per share Weighted average price for 20,000 common shares sold, with trades from $39.90 to $40.00

Sale price range $39.90–$40.00 per share Range of individual trade prices for the 20,000 shares sold

Remaining stock options 18,578 options Options held after the exercise reported in this filing

Option expiration date April 19, 2033 Expiration date of the stock options involved in the exercise

Rule 10b5-1 plan adoption date March 30, 2026 Date the trading plan governing the reported sales was adopted

Key Terms

weighted average price, Rule 10b5-1 trading plan, fully vested

3 terms

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 trading plan regulatory

"These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

fully vested financial

"Reflects an award of stock options to purchase Common Shares that is fully vested."

FAQ

What insider transactions did ROIV director Meghan Fitzgerald report on September 8, 2026?

She exercised 20,000 stock options for Roivant Sciences Ltd. common shares at $8.80 per share and then sold 20,000 common shares the same day at a weighted average price between $39.90 and $40.00 per share.

Was the September 8, 2026 sale of ROIV shares made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating the sale was pre-arranged under that plan.

How many Roivant Sciences (ROIV) options did Meghan Fitzgerald exercise and at what price?

She exercised 20,000 stock options for Roivant Sciences Ltd. common shares at an exercise price of $8.80 per share, receiving 20,000 common shares in connection with that exercise.

What price did Meghan Fitzgerald receive for the 20,000 ROIV shares sold?

The sale price reported is a weighted average of $39.90 per share, with individual trades executed at prices ranging from $39.90 to $40.00 per share, inclusive, for the 20,000 common shares sold.

How many Roivant Sciences (ROIV) stock options does Meghan Fitzgerald hold after the reported transactions?

After the September 8, 2026 option exercise, she holds 18,578 stock options for Roivant Sciences Ltd. common shares, and these options are reported to remain exercisable until April 19, 2033.

Are Meghan Fitzgerald’s reported Roivant Sciences (ROIV) options fully vested?

Yes. A footnote explains that the filing reflects an award of stock options to purchase Roivant Sciences Ltd. common shares that is fully vested, meaning they were fully exercisable at the time of the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 09:01 PM Accepted by SEC EDGAR 09/10/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Meghan

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/08/2026		M		20,000	A	$8.8	62,963	D
Common Shares	09/08/2026		S		20,000	D	$39.9(1)	42,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.8	09/08/2026		M			20,000	(2)	04/19/2033	Common Stock	20,000	$0	18,578	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Meghan FitzGerald	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)